J&J invests $500m into global HIV and TB treatment
10-10-2019
J&J reveals plans to appeal cancer drug court ruling
29-10-2018
PTAB invalidates Johnson & Johnson cancer drug patent
18-01-2018
16-05-2019
Gil C / Shutterstock.com
The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson (J&J) on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga (abiraterone acetate).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Johnson & Johnson, US Court of Appeals for the Federal Circuit, US Patent and Trial Appeal Board, Zytiga, prostate cancer drug, patent invalidation